These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23033348)

  • 1. Antihypertensive treatment prolongs tissue plasminogen activator door-to-treatment time: secondary analysis of the INSTINCT trial.
    Skolarus LE; Scott PA; Burke JF; Adelman EE; Frederiksen SM; Kade AM; Kalbfleisch JD; Ford AL; Meurer WJ
    Stroke; 2012 Dec; 43(12):3392-4. PubMed ID: 23033348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke.
    Lin CB; Peterson ED; Smith EE; Saver JL; Liang L; Xian Y; Olson DM; Shah BR; Hernandez AF; Schwamm LH; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):514-22. PubMed ID: 22787065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Impact of Implementation of a Stroke Protocol on Door-to-Needle Time in the Administration of Intravenous Tissue Plasminogen Activator.
    Hillen ME; He W; Al-Qudah Z; Wang W; Hidalgo A; Walia J
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):1569-1572. PubMed ID: 28411038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drill down analysis of door-to-needle time of acute ischemic stroke patients treated with intravenous tissue plasminogen activator.
    Schrock JW; Lum M
    Am J Emerg Med; 2014 Nov; 32(11):1330-3. PubMed ID: 25195044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany.
    Audebert HJ; Kukla C; Vatankhah B; Gotzler B; Schenkel J; Hofer S; Fürst A; Haberl RL
    Stroke; 2006 Jul; 37(7):1822-7. PubMed ID: 16763192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delay to Tissue Plasminogen Activator in Hypertensive Stroke Patients: An Analysis of Delay Duration Across Agents.
    Carrera JF; Sorace BJ; Worrall BB; Southerland AM; Chiota-McCollum NA
    J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104525. PubMed ID: 31812455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal Trends in Clinical Characteristics and Door-to-Needle Time in Patients Receiving Intravenous Tissue Plasminogen Activator: A Retrospective Study of 4 Hospitals in Japan.
    Tanaka K; Matsumoto S; Yamada T; Nagano S; Takase KI; Hatano T; Yamasaki R; Kira JI
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104305. PubMed ID: 31405791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does study enrollment delay treatment with intravenous thrombolytics for acute ischemic stroke?
    Martin-Schild S; Albright KC; Hallevi H; Barreto AD; Grotta JC; Savitz SI
    Stroke; 2009 Feb; 40(2):663. PubMed ID: 18948603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stop Stroke© Acute Care Coordination Medical Application: A Brief Report on Postimplementation Performance at a Primary Stroke Center.
    Dickson RL; Sumathipala D; Reeves J
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1275-1279. PubMed ID: 26971040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
    Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed Intravenous Thrombolysis in Patients with Minor Stroke.
    Yoo J; Sohn SI; Kim J; Ahn SH; Lee K; Baek JH; Kim K; Hong JH; Koo J; Kim YD; Kwak J; Nam HS; Heo JH
    Cerebrovasc Dis; 2018; 46(1-2):52-58. PubMed ID: 30092583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke.
    Kamal N; Sheng S; Xian Y; Matsouaka R; Hill MD; Bhatt DL; Saver JL; Reeves MJ; Fonarow GC; Schwamm LH; Smith EE
    Stroke; 2017 Apr; 48(4):946-954. PubMed ID: 28228574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline National Institutes of Health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke.
    Muchada M; Rubiera M; Rodriguez-Luna D; Pagola J; Flores A; Kallas J; Sanjuan E; Meler P; Alvarez-Sabin J; Ribo M; Molina CA
    Stroke; 2014 Apr; 45(4):1059-63. PubMed ID: 24603070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
    Xian Y; Xu H; Lytle B; Blevins J; Peterson ED; Hernandez AF; Smith EE; Saver JL; Messé SR; Paulsen M; Suter RE; Reeves MJ; Jauch EC; Schwamm LH; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28096207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Door-to-Needle Delays in Minor Stroke: A Causal Inference Approach.
    Rostanski SK; Shahn Z; Elkind MSV; Liberman AL; Marshall RS; Stillman JI; Williams O; Willey JZ
    Stroke; 2017 Jul; 48(7):1980-1982. PubMed ID: 28536170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of direct admission to Comprehensive Stroke Centers on the outcome of acute stroke patients treated with intravenous thrombolysis.
    Pérez de la Ossa N; Millán M; Arenillas JF; Sánchez-Ojanguren J; Palomeras E; Dorado L; Guerrero C; Dávalos A
    J Neurol; 2009 Aug; 256(8):1270-6. PubMed ID: 19353224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population.
    Kim JT; Fonarow GC; Smith EE; Reeves MJ; Navalkele DD; Grotta JC; Grau-Sepulveda MV; Hernandez AF; Peterson ED; Schwamm LH; Saver JL
    Circulation; 2017 Jan; 135(2):128-139. PubMed ID: 27815374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Door to Intravenous Tissue Plasminogen Activator Time and Hospital Length of Stay in Acute Ischemic Stroke Patients, Georgia, 2007-2013.
    Ido MS; Okosun IS; Bayakly R; Clarkson L; Lugtu J; Floyd S; Krompf K; Frankel M
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):866-71. PubMed ID: 26853143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in Door-to-Needle Time in Patients with Acute Ischemic Stroke via a Simple Stroke Activation Protocol.
    Tan BYQ; Ngiam NJH; Sunny S; Kong WY; Tam H; Sim TB; Leong BSH; Bhartendu C; Paliwal PR; Seet RCS; Chan BPL; Teoh HL; Sharma VK; Yeo LLL
    J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1539-1545. PubMed ID: 29422380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.